Literature DB >> 20107089

Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex.

Kevin S Akers1, Chris Chaney, Alice Barsoumian, Miriam Beckius, Wendy Zera, Xin Yu, Charles Guymon, Edward F Keen, Brian J Robinson, Katrin Mende, Clinton K Murray.   

Abstract

Antimicrobial resistance is depleting the pharmacopeia of agents clinically useful against Gram-negative bacilli. As the number of active agents diminishes, accurate susceptibility testing becomes critical. We studied the susceptibilities of 107 isolates of the Acinetobacter baumannii-calcoaceticus complex to amikacin, gentamicin, and tobramycin using disk diffusion, Etest, as well as the Phoenix, Vitek 2, and MicroScan automated systems, and compared the results to those obtained by broth microdilution. Genes encoding aminoglycoside-modifying enzymes (AMEs) were detected by multiplex PCR, and clonal relationships were determined by pulsed-field gel electrophoresis. Tobramycin was the most active aminoglycoside (27.1% of isolates were susceptible). Disk diffusion and Etest tended to be more accurate than the Vitek 2, Phoenix, and MicroScan automated systems; but errors were noted with all methods. The Vitek 2 instrument incorrectly reported that more than one-third of the isolates were susceptible to amikacin (a very major error). Isolates were polyclonal, with 26 distinct strains, and carried multiple AME genes unrelated to the strain type. The presence of the ant(2")-Ia gene was statistically associated with resistance to each aminoglycoside. The AME genotype accounted for the resistance profile observed in a minority of isolates, suggesting the involvement of multiple resistance mechanisms. Hospital pharmacy records indicated the preferential use of amikacin over other aminoglycosides in the burn intensive care unit, where aminoglycoside resistance is prevalent. The resistance in that unit did not correlate with a predominant strain, AME genotype, or total annual aminoglycoside consumption. Susceptibility to tobramycin increased, even though susceptible isolates carried AME genotypes predicting the inactivation of tobramycin. Determination of the relative contribution of multiple concurrent resistance mechanisms may improve our understanding of aminoglycoside resistance in the Acinetobacter baumannii-calcoaceticus complex.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20107089      PMCID: PMC2849581          DOI: 10.1128/JCM.02006-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes.

Authors:  David D Boehr; Kari-ann Draker; Kalinka Koteva; Manjeet Bains; Robert E Hancock; Gerard D Wright
Journal:  Chem Biol       Date:  2003-02

2.  Evaluation of the VITEK 2 system for rapid direct identification and susceptibility testing of gram-negative bacilli from positive blood cultures.

Authors:  Thomas K W Ling; Z K Liu; Augustine F B Cheng
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

3.  False susceptibility to amikacin by VITEK 2 in Acinetobacter baumannii harboring armA.

Authors:  Sunkyung Jung; Jin Kyung Yu; Sang Hyun Shin; Kang Gyun Park; Dong Wook Jekarl; Kyungja Han; Yeon-Joon Park
Journal:  Ann Clin Lab Sci       Date:  2010       Impact factor: 1.256

4.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

5.  Evaluation of the VITEK 2 system for the identification and susceptibility testing of three species of nonfermenting gram-negative rods frequently isolated from clinical samples.

Authors:  P Joyanes; M del Carmen Conejo; L Martínez-Martínez; E J Perea
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

6.  Substrate specificities and structure-activity relationships for the nucleotidylation of antibiotics catalyzed by aminoglycoside nucleotidyltransferase 2''-I.

Authors:  C A Gates; D B Northrop
Journal:  Biochemistry       Date:  1988-05-17       Impact factor: 3.162

7.  Identification of Acinetobacter genomic species by amplified ribosomal DNA restriction analysis.

Authors:  M Vaneechoutte; L Dijkshoorn; I Tjernberg; A Elaichouni; P de Vos; G Claeys; G Verschraegen
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Characterization of the chromosomal aac(6')-Ij gene of Acinetobacter sp. 13 and the aac(6')-Ih plasmid gene of Acinetobacter baumannii.

Authors:  T Lambert; G Gerbaud; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.

Authors:  J F Levine; M J Maslow; R E Leibowitz; A A Pollock; B A Hanna; S Schaefler; M S Simberkoff; J J Rahal
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

10.  Nosocomial outbreaks due to amikacin-resistant tobramycin-sensitive Acinetobacter species: correlation with amikacin usage.

Authors:  Y Buisson; G Tran Van Nhieu; L Ginot; P Bouvet; H Schill; L Driot; M Meyran
Journal:  J Hosp Infect       Date:  1990-01       Impact factor: 3.926

View more
  28 in total

1.  A novel New Delhi metallo-β-lactamase variant, NDM-14, isolated in a Chinese Hospital possesses increased enzymatic activity against carbapenems.

Authors:  Dayang Zou; Yong Huang; Xiangna Zhao; Wei Liu; Derong Dong; Huan Li; Xuesong Wang; Simo Huang; Xiao Wei; Xiabei Yan; Zhan Yang; Yigang Tong; Liuyu Huang; Jing Yuan
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

2.  Modifying enzymes related aminoglycoside: analyses of resistant Acinetobacter isolates.

Authors:  Ali Riza Atasoy; Ihsan Hakki Ciftci; Mustafa Petek
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

4.  Emergence of the first levofloxacin-resistant strains of Streptococcus agalactiae isolated in Italy.

Authors:  G Piccinelli; F Gargiulo; S Corbellini; G Ravizzola; C Bonfanti; A Caruso; M A De Francesco
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

5.  Effect of solvent and protein dynamics in ligand recognition and inhibition of aminoglycoside adenyltransferase 2″-Ia.

Authors:  Valjean R Bacot-Davis; Angelia V Bassenden; Tara Sprules; Albert M Berghuis
Journal:  Protein Sci       Date:  2017-07-21       Impact factor: 6.725

6.  Antibiotic resistance and expression of resistance-nodulation-division pump- and outer membrane porin-encoding genes in Acinetobacter species isolated from Canadian hospitals.

Authors:  Dinesh Fernando; George Zhanel; Ayush Kumar
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

7.  Detection of antibiotic resistance profiles and aminoglycoside-modifying enzyme (AME) genes in high-level aminoglycoside-resistant (HLAR) enterococci isolated from raw milk and traditional cheeses in Turkey.

Authors:  Rahime Özdemir; Yasin Tuncer
Journal:  Mol Biol Rep       Date:  2020-01-27       Impact factor: 2.316

8.  Carbapenem susceptibility testing errors using three automated systems, disk diffusion, Etest, and broth microdilution and carbapenem resistance genes in isolates of Acinetobacter baumannii-calcoaceticus complex.

Authors:  Ana Elizabeth Markelz; Katrin Mende; Clinton K Murray; Xin Yu; Wendy C Zera; Duane R Hospenthal; Miriam L Beckius; Tatjana Calvano; Kevin S Akers
Journal:  Antimicrob Agents Chemother       Date:  2011-08-01       Impact factor: 5.191

9.  Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration.

Authors:  Kevin S Akers; Jason M Cota; Christopher R Frei; Kevin K Chung; Katrin Mende; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

Review 10.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.